Industry litigation – Page 21
-
Business
Does chemical regulation boost innovation?
Report suggests that supply of innovation responds to extra demand created by new laws
-
Business
Merck resolves Vytorin case for $688m
Investors say the company knew about Enhance trial failure but withheld information
-
Business
GSK commits to AllTrials data disclosure
Company will begin publishing all clinical study reports
-
BusinessEU proposes neonicotinoid pesticide ban
Clothianidin, thiamethoxam and imidacloprid at centre of debate over declining bee populations
-
BusinessIndia pushes for emergency drug licences
Government looks set to force licensing of three patented cancer drugs
-
Business
Laropiprant recalled
Merck & Co says it is recalling Tredaptive tablets, approved in the EU for treating patients with high cholesterol
-
Business2012 pharma industry roundup
What were the bigger stories? And how did the industry fare overall?
-
Business
Single EU patent agreed for 2014
European commission says long awaited single patent will cut cost of filing by 87%
-
Business
Roche and the Tamiflu data
Company position on access to data for antiviral Tamiflu (oseltamivir) tablets could be softening
-
BusinessRecord insider trading case hits pharma
US authorities claim that hedge fund manager made illicit gains of $276 million in response to confidential clinical trial data
-
Business
BP to pay £4.5 billion for disaster
Company will plead guilty to criminal charges including felony manslaughter
-
Business
Panel delivers final PFOA report
Probable link between perfluorooctanoic acid, used by DuPont to make fluoro-polymers, and high cholesterol
-
BusinessChemists contribute to prior art hunt
A crowdsourcing website that pays for prior art is gaining popularity – can chemists make money?
-
Business
Patent woes lead to sharp sales losses
Bristol-Myers Squibb, AstraZeneca and Eli Lilly have all suffered loss of exclusivity for key drugs
-
Business
Problems for Russian chemicals?
Accession to WTO will force government to ditch badly needed subsidies
-
Business
Teva pulls generic antidepressant
FDA rules that Budeprion XL is not equivalent to Wellbutrin XL
-
Business
Dow tax case raises R&D questions
US court blocks Dow attempt to recoup costs under the R&D tax credit scheme
-
Business
Kevlar equivalent banned for 20 years
US rules in favour of DuPont in Kevlar trade secrets case
-
BusinessCrowdsourcing science site to launch
Marblar aims to find uses for neglected patents by ‘gamifying’ the technology transfer process